Our Mission:
To develop novel therapies for the treatment of traumatic brain injury, as it remains one of the greatest unsolved problems in critical trauma today, and a leading cause of death and major disability.
Overview
Cellvation, Inc., is a clinical‐stage biopharmaceutical company developing novel cellular therapeutics for the treatment of traumatic brain injury (“TBI”). Cellvation is developing CEVA‐D, a novel bioreactor that enhances the anti‐inflammatory potency of bone marrow‐derived cells without genetic manipulation. CEVA-102 is based on cellular products derived from our proprietary device, CEVA-D, and shall also initially be studied in TBI.
Cellvation is a majority‐owned subsidiary of Fortress Biotech (NASDAQ: FBIO) and is based in New York City.